Product Launch

Phytopharm PLC
26 March 2007


Company Contact:                                U.K. Investor Relations Contact:
Phytopharm plc                                  Financial Dynamics
Dr Daryl Rees CEO                               David Yates
Mr Piers Morgan CFO                             Ben Atwell
[phone]                                [phone]
www.phytopharm.com


                    Launch of PhytopicaTM in Italy

GODMANCHESTER, Cambridgeshire, U.K. (26 March 2007) - Phytopharm plc (LSE: PYM)
('Phytopharm' or the 'Company') today announces the launch of PhytopicaTM in
Italy by its partner, Schering-Plough Animal Health ('Schering-Plough').

In January 2006, Phytopharm entered into an exclusive global agreement with
Schering-Plough for the Company's canine skin health product, PhytopicaTM.
Under the terms of the agreement, Phytopharm is responsible for manufacturing
PhytopicaTM whilst Schering-Plough is responsible for the global sales,
marketing and distribution of PhytopicaTM.  In April 2006, Schering-Plough
launched PhytopicaTM in the UK and the product has enjoyed firm support from
veterinary dermatologists and recorded strong sales growth.

PhytopicaTM is effective in the management of canine skin health by providing a
novel 3 in 1 approach to help maintain a normal healthy immune system, support
normal white cell function and provide anti-oxidant benefits.  The beneficial
effects and excellent safety profile of PhytopicaTM have been proven extensively
in clinical trials and the product has been found to be suitable for all dogs
whatever size or breed.  Following the Italian launch, Schering-Plough will seek
to market and distribute PhytopicaTM in further major territories in Europe and
the USA.


Commenting on today's announcement, Dr Daryl Rees, Chief Executive Officer of
Phytopharm, said: 'We are delighted with the launch of PhytopicaTM in Italy by
one of the world's leading animal health companies.  PhytopicaTM sales in the UK
have exceeded our expectations and with Schering-Plough's Italian launch we look
forward to further growth.'


Commenting on today's announcement, Dr Luciano Cora, Companion Animal Manager at
Schering-Plough, Italy said: 'We are very pleased to be launching PhytopicaTM in
Italy as it offers a safe and cost effective approach to the management of
canine skin health.  Following the success in the UK and the increasing demand
for safe and effective companion animal products in Italy, we look forward to
maximizing the potential of PhytopicaTM.'



                                      -ENDS-

NOTES TO EDITORS



Phytopharm plc

Phytopharm is a pharmaceutical development and functional food company whose
product leads are generated from medicinal plants.  The Company's strategy is to
develop these products through 'proof of principle' clinical testing, and then
secure partners for late stage development, sales and marketing. Laboratory,
manufacturing and clinical work is outsourced to selected specialists, operating
under expert in-house management.  This operational structure allows access to
advanced research techniques whilst maintaining low fixed overheads and a lower
development cost structure.



Canine dermatological disorders are recognised by veterinarians to be a major
problem in small animal practice, with an estimated 15-30% of the global dog
population affected by skin conditions (Muller & Kirk's Small Animal
Dermatology, 6th Ed, 2000).



For further information about Phytopharm please see our website at 
http://www.phytopharm.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange